Search Instructions:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (107 total)
-
Creator: the PlasmAr Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-18
Description: Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled… -
Creator: the Fundación INFANT–COVID-19 Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-18
Description: Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier… -
Creator: Schafer, Adam, Rui Xiong, Laura Cooper, Raghad Nowar, Hyun Lee, Yangfeng Li, Benjamin E. Ramirez, Norton P. Peet, Michael Caffrey, Gregory R. J. Thatcher, Erica Ollmann Saphire, Han Cheng, and Lijun Rong.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-04
Description: Many small molecules have been identified as entry inhibitors of filoviruses. However, a lack of understanding of the mechanism of action for these molecules limits further their development as anti-filoviral agents. Here we provide evidence that… -
Creator: The RECOVERY Collaborative Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-02
Description: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.A response to this article was… -
Creator: NETEC
Subject: Treatment & Care
Item Type: Guide
Date Last Updated: 2020-12-10
Description: This printable flyer infographic discusses mAb for COVID-19. Monoclonal antibody therapeutics (mAb) are one of the first available medical countermeasure therapeutics for mild-to-moderate COVID-19 cases. This handout discusses what they are, the… -
Creator: Huang, Edmund, and Stanley C. Jordan.
Subject: Research
Item Type: Publication
Date Last Updated: 2020-12-10
Description: Nearly 10 months after the identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the virus responsible for coronavirus disease 2019 (Covid-19), therapeutic options remain limited. -
Creator: WHO Solidarity Trial Consortium
Subject: Research
Item Type: Publication
Date Last Updated: 2020-12-02
Description: World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with coronavirus disease 2019 (Covid-19). -
Creator: NETEC
Subject: Treatment & Care
Item Type: Webinar
Date Last Updated: 2020-11-25
Description: In this webinar, we will identify important considerations involving Monoclonal Antibody Therapeutics available for emergency use authorization (EUAs) for mild-to-moderate COVID-19 cases, discuss recent criteria for the FDA approved investigational… -
Creator: Cavalcanti, Alexandre B., Fernando G. Zampieri, Regis G. Rosa, Luciano C. P. Azevedo, Viviane C. Veiga, Alvaro Avezum, Lucas P. Damiani, Aline Marcadenti, Letícia Kawano-Dourado, Thiago Lisboa, Debora L. M. Junqueira, Pedro G. M. de Barros e Silva,…
Subject: Research
Item Type: Publication
Date Last Updated: 2020-11-19
Description: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited. -
Creator: The RECOVERY Collaborative Group
Subject: Research
Item Type: Publication
Date Last Updated: 2020-11-19
Description: Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials.